Audentes Therapeutics (BOLD) Given New $48.00 Price Target at Svb Leerink

Audentes Therapeutics (NASDAQ:BOLD) had its price objective boosted by Svb Leerink from $37.00 to $48.00 in a report issued on Wednesday, April 17th, Stock Target Advisor reports. Svb Leerink currently has an outperform rating on the biotechnology company’s stock.

A number of other equities research analysts also recently weighed in on BOLD. ValuEngine upgraded shares of Audentes Therapeutics from a buy rating to a strong-buy rating in a research note on Monday, April 1st. Zacks Investment Research upgraded shares of Audentes Therapeutics from a hold rating to a buy rating and set a $39.00 price objective for the company in a research note on Tuesday, March 5th. Piper Jaffray Companies upped their target price on shares of Audentes Therapeutics from $45.00 to $55.00 and gave the stock a positive rating in a research note on Monday, April 8th. HC Wainwright reiterated a buy rating and issued a $44.00 target price (up previously from $33.00) on shares of Audentes Therapeutics in a research note on Monday, March 18th. Finally, William Blair reiterated a hold rating on shares of Audentes Therapeutics in a research note on Wednesday, February 27th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $39.92.

BOLD stock traded up $0.27 during mid-day trading on Wednesday, hitting $38.58. The stock had a trading volume of 279,121 shares, compared to its average volume of 573,400. Audentes Therapeutics has a 52 week low of $17.95 and a 52 week high of $46.18. The firm has a market cap of $1.71 billion, a P/E ratio of -11.35 and a beta of 1.85.

Audentes Therapeutics (NASDAQ:BOLD) last released its earnings results on Tuesday, May 7th. The biotechnology company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.23). During the same quarter in the previous year, the company earned ($0.74) EPS. As a group, equities research analysts forecast that Audentes Therapeutics will post -4.07 EPS for the current fiscal year.

In other Audentes Therapeutics news, VP Suyash Prasad sold 10,000 shares of the company’s stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $30.06, for a total transaction of $300,600.00. Following the sale, the vice president now directly owns 28,236 shares of the company’s stock, valued at $848,774.16. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Matthew R. Patterson sold 21,000 shares of the company’s stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $30.00, for a total transaction of $630,000.00. Following the sale, the chief executive officer now directly owns 135,700 shares in the company, valued at $4,071,000. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 51,000 shares of company stock worth $1,650,600. Insiders own 6.60% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Principal Financial Group Inc. bought a new position in shares of Audentes Therapeutics in the first quarter worth approximately $229,000. Jennison Associates LLC increased its position in shares of Audentes Therapeutics by 31.5% in the first quarter. Jennison Associates LLC now owns 1,346,970 shares of the biotechnology company’s stock worth $52,559,000 after purchasing an additional 322,279 shares during the last quarter. Federated Investors Inc. PA increased its position in shares of Audentes Therapeutics by 117.7% in the first quarter. Federated Investors Inc. PA now owns 303,023 shares of the biotechnology company’s stock worth $11,824,000 after purchasing an additional 163,824 shares during the last quarter. Swiss National Bank increased its position in shares of Audentes Therapeutics by 3.4% in the first quarter. Swiss National Bank now owns 66,100 shares of the biotechnology company’s stock worth $2,579,000 after purchasing an additional 2,200 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Audentes Therapeutics by 13.0% in the first quarter. Dimensional Fund Advisors LP now owns 637,536 shares of the biotechnology company’s stock worth $24,875,000 after purchasing an additional 73,489 shares during the last quarter. Hedge funds and other institutional investors own 97.40% of the company’s stock.

About Audentes Therapeutics

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Featured Story: Dividend

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.